Home | Welcome to Contract Pharma   
Last Updated Saturday, July 26 2014
Print RSS Feed

Topics - APIs


Refine by Date:
From: To:
Published July 22, 2014
Will support a portfolio of drug substance campaigns Read More »
Published July 22, 2014
Will produce NME for U.S. market Read More »
Published July 21, 2014
Phase IIa trial scheduled for 2014 Read More »
Published June 23, 2014
Expands GMP manufacturing services for APIs Read More »
Published May 20, 2014
Secures additional manufacturing capacity for Patiromer Read More »
Published May 13, 2014
Provided process development and production of Neuronascent’s lead candidate NNI-362 Read More »
Published May 1, 2014
EDQM certifies Dimethyl Sulfoxide suitability Read More »
Published April 9, 2014
Aims to support long-term growth efforts Read More »
Published April 8, 2014
To provide APIC with additional capacity for APIs and intermediates Read More »
By Kristin Brooks
Published March 24, 2014
Expands custom API products and services Read More »
By Kristin Brooks
Published March 11, 2014
Aims to sell generic Nexium in the U.S., despite regulatory restrictions Read More »
By Gil Roth
Published February 6, 2014
Generic exclusivity boosts 4Q revenues Read More »
By Gil Roth
Published February 5, 2014
First-year goals met Read More »
By Andrew Badrot, CMS Pharma
Published January 30, 2014
DSM & Patheon unlock value through a creative merger Read More »
By Kristin Brooks
Published January 29, 2014
To produce a new class of APIs called viral vectors Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On